If you feel like you are experiencing deja vu at the start of this earnings season, you aren’t mistaken. In similar fashion to the Q1 season, we head into second quarter reports after hitting a fresh S&P 500 intraday high of 4,365.89 on Friday f
Read More
S&P 500 firms have easily beaten analyst earnings expectations four quarters in a row—the drive for five is on! We feature two earnings outliers this week as the second quarter reporting season begins.
Read More
Nearly 16 months after the COVID-19 pandemic halted in-person movie-going, studios are hoping pent-up demand will feed box office numbers this summer.
Read More
Conferences, forums, summits, and trade shows are among the most important events traders must mark on their calendars. Stock-specific news is often released at these gatherings of executives, analysts, and industry experts.
Read More
Traders are gearing up for another earnings season. S&P 500 companies have handily beaten analyst expectations in each of the last four reporting periods, so expectations are likely growing loftier.
Read More
Prescription Drug User Fee Act (PDUFA) dates and content are essential for portfolio managers of healthcare stocks. A single positive or negative announcement from the US Food and Drug Administration (FDA) can send shares of a biotech firm soaring or turn
Read More
This week, we feature insights on what companies are doing with their cash flow in light of the much better than expected operating conditions. We also investigate one small U.S. firm as an Earnings Outlier that traders should keep on their radar.
Read More
The emerging theme is, “what will firms do with capital now that lending standards are easing and companies are ripe with cash?” M&A, returning value to shareholders, and rising wages are three routes corporate managers can take. We hear h
Read More
